Vera Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.veratx.com

Safety Score

Market Cap $2.59B
PE -19
Debt $50.47M
Cash $27.26M
EV $2.62B
FCF -$121.03M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$134.38M
EBIT	-$139.26M
ROE	-46%
ROA	-38%
FCF	-$121.03M
Equity	$289.06M
Growth Stability	1
PE	-19.31
PB	8.98
P/FCF	-21.44
Price/Cash	0.01
Debt/Equity	0.17
Debt/FCF	-0.42
Equity CAGR	44%
Earnings Growth YoY	132%
Earnings Growth QoQ	38%

Equity CAGR 5Y	44%
Equity CAGR 3Y	57%
Market Cap	$2.59B
Assets	$368.56M
Total Debt	$50.47M
Cash	$27.26M
Shares Outstanding	53.54M
EV	2.62B
Safety Score	65%
Working Capital	337.67M
Current Ratio	13.76
Shares Growth 3y	39%
Equity Growth QoQ	-12%
Equity Growth YoY	134%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

SEC Filings

Direct access to Vera Therapeutics, Inc. (VERA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vera Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vera Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vera Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vera Therapeutics, Inc..

Years

Calculation mode

= -$1.2B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$121M	-$121M	-$121M	-$121M	-$121M	-$121M	-$121M	-$121M	-$121M	-$121M	-$121M	-$1.2B
DCF		-$110M	-$100M	-$91M	-$83M	-$75M	-$68M	-$62M	-$56M	-$51M	-$47M	-$467M
Value	-$1.2B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-	-	-	-	-
ROA	-	-39%	-68%	-55%	-38%
ROE	-	-47%	-116%	-94%	-46%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.17	-0.37	-0.54	-0.42
Debt over Equity	-0	0.07	0.33	0.49	0.17
Growth Stability	-	-	-	-	1

Good Debt/FCF ratio (-0.42)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.17)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-	-	-	-
Earnings YoY growth	-	-39%	173%	8%	-
Equity YoY growth	-	-178%	11%	32%	44%
FCF YoY growth	-	-18%	136%	36%	-